Use of Hormone Therapy in Women with Early Menopause and Premature Ovarian Insufficiency

Abstract

Women with early menopause or primary ovarian insufficiency (POI) experience a menopausal state a decade or more earlier than their peers. The health consequences for POI are vast and varied with detrimental effects seen on neurological, psychological, bone, and cardiovascular systems. The risk profile of POI patients requires special attention, as they differ from a typical menopausal population. This review will explore the health risks associated with POI and examine the various treatment options and also the risks associated with hormone therapy. Given the risks and benefits, POI patients should be strongly encouraged to start hormone therapy until the median age of menopause.

Keywords

premature menopause - early menopause - primary ovarian insufficiency - hormone therapy

Publication History

Article published online:
04 February 2021

• References

• 1 van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997; 68 (01) 95-102
• 2 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67 (04) 604-606
• 3 Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsjö G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health 2018; 18 (01) 175
• 4 Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360 (06) 606-614
• 5 Honigberg MC, Zekavat SM, Aragam K. et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019; (online ahead of print)
• 6 Ley SH, Li Y, Tobias DK. et al. Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women. J Am Heart Assoc 2017; 6 (11) e006713
• 7 Zhu D, Chung HF, Dobson AJ. et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019; 4 (11) e553-e564
• 8 Bairey Merz CN, Johnson BD, Sharaf BL. et al; WISE Study Group. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 2003; 41 (03) 413-419
• 9 Kok HS, van Asselt KM, van der Schouw YT. et al. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol 2006; 47 (10) 1976-1983
• 10 Stuenkel CA. Cardiovascular risk and early menopause: cause or consequence?. Menopause 2012; 19 (10) 1067-1069
• 11 Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91 (01) 12-15
• 12 Popat VB, Calis KA, Kalantaridou SN. et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement. J Clin Endocrinol Metab 2014; 99 (09) 3418-3426
• 13 van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003; 14 (06) 525-530
• 14 Greendale GA, Huang M, Cauley JA. et al. Trabecular bone score declines during the menopause transition: the Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab 2020; 105 (04) e1872-e1882
• 15 Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 2016; 106 (07) 1588-1599
• 16 Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol 2001; 98 (01) 85-90
• 17 Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71 (04) 717-721
• 18 McSorley MA, Alberg AJ, Allen DS. et al. Prediagnostic circulating follicle stimulating hormone concentrations and ovarian cancer risk. Int J Cancer 2009; 125 (03) 674-679
• 19 Irvin SR, Weiderpass E, Stanczyk FZ. et al. Association of anti-Mullerian hormone, follicle-stimulating hormone, and inhibin B with risk of ovarian cancer in the Janus Serum Bank. Cancer Epidemiol Biomarkers Prev 2020; 29 (03) 636-642
• 20 Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385 (9980): 1835-1842
• 21 Brieger KK, Peterson S, Lee AW. et al; Ovarian Cancer Association Consortium. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol 2020; 158 (03) 702-709
• 22 Lee AW, Wu AH, Wiensch A. et al; Ovarian Cancer Association Consortium. Estrogen plus progestin hormone therapy and ovarian cancer: a complicated relationship explored. Epidemiology 2020; 31 (03) 402-408
• 23 Harlow BL, Cramer DW, Annis KM. Association of medically treated depression and age at natural menopause. Am J Epidemiol 1995; 141 (12) 1170-1176
• 24 Allshouse AA, Semple AL, Santoro NF. Evidence for prolonged and unique amenorrhea-related symptoms in women with premature ovarian failure/primary ovarian insufficiency. Menopause 2015; 22 (02) 166-174
• 25 Schmidt PJ, Luff JA, Haq NA. et al. Depression in women with spontaneous 46, XX primary ovarian insufficiency. J Clin Endocrinol Metab 2011; 96 (02) E278-E287
• 26 van der Stege JG, Groen H, van Zadelhoff SJ. et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008; 15 (01) 23-31
• 27 Kalantaridou SN, Naka KK, Papanikolaou E. et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89 (08) 3907-3913
• 28 de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011; 18 (03) 262-266
• 29 Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using hormonal therapy and vaginal health. Climacteric 2014; 17 (04) 342-347
• 30 Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19 (02) 114-124
• 31 Mittal M, Kreatsa M, Narvekar N, Savvas M, Hamoda H. Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre. Post Reprod Health 2014; 20 (03) 104-111
• 32 Benetti-Pinto CL, de Almeida DM, Makuch MY. Quality of life in women with premature ovarian failure. Gynecol Endocrinol 2011; 27 (09) 645-649
• 33 Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015; 18 (04) 483-491
• 34 Committee on Gynecologic Practice. Committee Opinion No. 698: hormone therapy in primary ovarian insufficiency. Obstet Gynecol 2017; 129 (05) e134-e141
• 35 Gu Y, Xu Y. Successful spontaneous pregnancy and live birth in a woman with premature ovarian insufficiency and 10 years of amenorrhea: a case report. Front Med (Lausanne) 2020; 7: 18
• 36 Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44 (02) 62-69
• 37 Chlebowski RT, Anderson GL, Aragaki AK. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA 2020; 324 (04) 369-380
• 38 International Breast Cancer Intervention Study Risk Assessment Tool. Accessed November 23, 2020 at: https://ibis.ikonopedia.com/
• 39 National Cancer Institute. The Breast Cancer Risk Assessment Tool. Published 2020. Accessed November 23, 2020 at: https://bcrisktool.cancer.gov/
• 40 Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336 (7655): 1227-1231
• 41 Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364: k4810
• 42 Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33 (05) 1190-1194
• 43 Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric 2012; 15 (03) 229-234
• 44 Wassertheil-Smoller S, Kaplan RC, Salazar CR. Stroke findings in the Women's Health Initiative. Semin Reprod Med 2014; 32 (06) 438-446
• 45 Manson JE, Aragaki AK, Rossouw JE. et al; WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative Randomized Trials. JAMA 2017; 318 (10) 927-938
• 46 Liu B, Beral V, Balkwill A, Green J, Sweetland S, Reeves G. Million Women Study Collaborators. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337: a386
• 47 Million Women Study Collaborative Group. The Million Women Study: design and characteristics of the study population. Breast Cancer Res 1999; 1 (01) 73-80
• 48 Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994; 83 (01) 5-11
• 49 Cordina-Duverger E, Truong T, Anger A. et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013; 8 (11) e78016
• 50 Jiang Y, Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis 2017; 16 (01) 219
• 51 Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow D, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20 (09) 2653-2660
• 52 Guerrieri GM, Martinez PE, Klug SP. et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause 2014; 21 (09) 952-961
• 53 Davis SR, Baber R, Panay N. et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019; 104 (10) 4660-4666
• 54 Webber L, Davies M, Anderson R. et al; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31 (05) 926-937
• 55 Popat VB, Calis KA, Vanderhoof VH. et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 2009; 94 (07) 2277-2283
• 56 Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 2016; 101 (09) 3497-3505
• 57 Crofton PM, Evans N, Bath LE. et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (Oxf) 2010; 73 (06) 707-714
• 58 Langrish JP, Mills NL, Bath LE. et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 2009; 53 (05) 805-811
• 59 National Academies of Sciences, Engineering, and Medicine, The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington, DC: The National Academies Press; 2020
• 60 Muka T, Oliver-Williams C, Kunutsor S. et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol 2016; 1 (07) 767-776
• 61 Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric 2016; 19 (01) 27-36
• 62 Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23 (02) 178-186
• 63 McNicholl DM, Heaney LG. The safety of bisphosphonate use in pre-menopausal women on corticosteroids. Curr Drug Saf 2010; 5 (02) 182-187
• 64 Holick MF, Binkley NC, Bischoff-Ferrari HA. et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96 (07) 1911-1930